Utilizing BioReinnovation’s Platform to Accelerate Innovation in DAR1 ADC/AXC & Dual Payload ADCs via Pure Chemo Approach
12:30 pm - Wednesday 14th October 2026
- Powering next-generation ADC/AXC innovation through four integrated core technology platforms (Conjugation: MCLICK, Linker-Payload: HILT, Ultra-Low DAR: UDAC, Dual Payload ADC: DPAC)
- Deploying UDAC platform to unlock precision redefined DAR1 therapeutic potential across ADC, AOC and APC modalities
- Breaking therapeutic barriers and unleashing dual payload synergy via MCLICK and HILT platform integration
